The objective of this study was to develop and validate a series of schizophrenia specific risk adjustment cost models. METHODS: Georgia Medicaid claims data linked with institutional inpatient data for 21,602 continuous eligible persons suffering from schizophrenia was used to build a prospective diagnosis-based, a demographic-based, a drug-based, and a combined risk adjustment cost model. ICD-9-CM and drug category classifications were derived from the literature and supplemented by an expert panel. Variables were screened and cost weights were derived empirically in a random 50% training sample using a robust a weighted Heuber-White regression model and validated by expert panel review, bootstrapping methods, and assessing indices of discrimination in a 50% validation sample. Model calibration and correlations of errors with policy relevant groups were also estimated. RESULTS: Measures of discrimination (R2) varied between 16.4% for the ICD-9-CM based model to 21.8% for the combined model for trimmed total cost and varied between 4.9% to 11.3% for mental health costs in the validation sample. Risk adjustment models based on drug or ICD-9-CM information discriminated costs equally well and the combined models outperformed both drug and ICD-9-CM based models. A simple model using prior year costs combined with demographic covariates had R2s > 40% for both mental health and total costs. CONCLUSIONS: The drug and ICD-9-CM based models performed equally well and either can be used with equal confidence depending on data availability. The combined models performed better than either the ICD-9-CM or drug based models indicating that drug exposure information can compliment more traditional approaches. Health services researchers wishing to control for differences in comorbidity and severity that influence cost should always consider including prior utilization (costs) since prior year costs were vastly superior predictors of costs. PMD45
OBJECTIVES:
To determine the most effective way to determine risk benefit ratios in phase 1-2 developmental compounds. The EMEA and FDA have recently published discussion documents on the need to incorporate an assessment of risk benefit ratios during pharmaceutical development. While methods are established for the formal analysis of later stage development, the method to assess risk in early development is unclear. This paper seeks to identify what methods are available and assess their application to risk-benefit assessment in early stage products. METHODS: A literature review of the methods used to assess new technology risks. The nature of the risks involved in early stage (phase 1 and 2) pharmaceutical development were also identified from a database, and the core values of the risks determined by established frameworks. RESULTS: Four main methods were determined: formal analysis, bootstrapping, trade off and, judgement analysis. In the analysis of the nature of the risks of phase 1/2 pharmaceutical development much of the risk can be described as voluntary risk, due to the informed consent process. The acceptance of risk will therefore vary with the severity of the condition and the equity of the treatment being offered. The remainder of the risk is outcome related, and so needs to be viewed in the context of the aims of treatment. Comparing the methods used to assess risk, only Judgement Analysis was able to incorporate the degree of voluntary risk encountered in the risk assessment of pharmaceuticals in early development. CONCLUSIONS: The finding that Judgement Analysis is the only method to assess risk benefit in early stage development is controversial as it runs against the statistical methods favoured by the regulators. The results indicate a strong need to educate ethics committees and other clinical trial professionals in a wider range of outcomes research.
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PROCESS UTILITY DERIVED FROM PROVIDING INFORMAL CARE
Brouwer WBF 1 ,Van Exel J 2 ,Van den Berg B 2 , Koopmanschap M 1 1 Erasmus University Rotterdam, Rotterdam, Netherlands; 2 Erasmus Medical Centre Rotterdam, Rotterdam, Netherlands OBJECTIVES: Though economics is usually outcomeoriented, it is often argued that processes matter as well. Utility is not only derived from outcomes, but also from the way this outcome is accomplished. Providing care on a voluntary basis may especially be associated with such process utility. In this paper we discuss the process utility from providing informal care. We test the hypothesis that informal caregivers derive utility not only from the outcome of informal care, i.e. that the patient is adequately cared for, but also from the process of providing informal care. METHODS: We measure process utility as the difference in utility between the current situation in which the care recipient is cared for by the caregiver and the hypothetical situation that someone else takes over the care tasks, all other things equal. We present empirical evidence of process utility on the basis of a large sample of Dutch caregivers (n = 950) and analyse these.
RESULTS:
Our results show that process utility exists and is substantial and therefore important in the context of informal care. Almost half of the caregivers (48.2%) derive positive utility from informal care and on average happiness would decline if informal care tasks were handed over to someone else. The multivariate analysis shows that process utility is significantly related to, amongst other things, age and gender of the caregiver. Male caregivers have lower process utility than female caregivers. Closer relationship (partner, parent, child) elicit lower process utility than others. CONCLUSIONS: Process utility is impotant in the context of informal care. Our results strengthen the idea of supporting informal care, but also that of keeping a close eye on the position of carers.
METHODOLOGICAL ISSUES-Utility Studies
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CALCULATING UTILITY VALUES FROM SF-36:
A COMPARISON OF DIFFERENT ALGORITHMS Svensson K AstraZeneca R&D Lund, Sweden, Lund, Sweden
OBJECTIVES:
This study aims to investigate if the results of four published algorithms for calculating utility values from assessments of SF-36 are in agreement with the responses of traditional efficacy variables assessed in a randomized clinical study with different treatments of asthmatic patients. METHODS: Data from a randomized clinical study of moderate asthmatic patients comparing treatment with budesonide alone (n = 114) with budesonide plus formoterol (n = 109) during 12 weeks are used in this investigation. Utility values from the four algorithms are calculated for the different treatment groups at randomization and at end of treatment, and both absolute values as well as change during treatment are correlated with efficacy variables assessed in the study: PEF Morning, FEV1, and the summary score SF-36 PCS from the SF-36 questionnaire. RESULTS: Mean Utility values at baseline range between 0.61 to 0.82 for the 4 algorithms but with no difference between the two treatment groups. Change during treatment varies between 0.08 and 0.11. While both PEF Morning and FEV1 are statistically significant when comparing the change during treatment between the two treatment groups, neither any of the SF-36 domains nor SF-36 PCS turns out to be. Two out of the four utility measures, both based on TTO, reaches statistical significance. Correlation for change during treatment shows moderate correlation with PEF Morning (0.28 to 0.32) and FEV1 (0.17 to 0.25). CON-CLUSION: The two utility measures based on the SF-36 items (or a subset thereof) and evaluated through TTO show better response than the other two, one evaluated through a Visual Analog Scale as rating scale, and the other based on domain values and not item values from SF-36.
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RELATIVE WEIGHTS ASSIGNED TO DRUGS AND BIOLOGICALS: OPPS METHODS AND CONCEPTS
Baker JJ University of Rochester, Pickton, TX, USA OBJECTIVE: The Centers for Medicare and Medicaid Services (CMS) assigns a relative weight to those high cost new technology drugs designated with a nonpass-through or expired pass-through payment status. This study examines the conceptual approach of relative weights for drugs and biologicals under the CMS Hospital Outpatient Prospective Payment System (OPPS) and compares this approach to the resource-based level of effort concept initially created for payment to physicians' offices in the U.S. METHODS: The underlying intent of relative value units (RVUs) in the physician's office was to create a hierarchy of resource-based level of effort involved in various types of office-based service delivery. The concept of hospital OPPS was also intended to reflect resource-based services. Thus the OPPS relative weights should be related to resource-based levels of effort. Non-pass-through high cost new technology drugs that are paid separately under OPPS are assigned a relative weight, implying that the payment includes level of effort resources. We postulate these relative weights contain no such level of effort, but instead represent only the pure drug component. This use of the relative weight concept distorts its initial intent. RESULTS: Resource-based methods initially proposed for the hospital OPPS were collected and deconstructed. CMS rationale supporting treatment of non-pass-through high cost new technology drugs paid separately under OPPS was identified. CMS drug payment computation methods were likewise deconstructed and evaluated. The evaluation sought indications of resource-based level of effort applications. CONCLU-SIONS: Many researchers and policy makers assume that relative weights equate to level of effort resource consumption in all instances. We cannot find this is so in the case of non-pass-through high cost new technology drugs paid separately under OPPS. It is necessary to draw CMS attention to this issue, as the volume of forthcoming new drugs and biologics means the issue will become increasingly important.
